Combination therapy for hepatocellular carcinoma: Additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib

BACKGROUND & AIMS: Hepatocellular carcinoma (HCC) is a heterogeneous cancer in which sorafenib is the only approved systemic therapy. Histone deacetylases (HDAC) are commonly dysregulated in cancer and therefore represent promising targets for therapies, however their role in HCC pathogenesis is...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Lachenmayer, Anja, Toffanin, Sara, Cabellos, Laia, Alsinet, Clara, Hoshida, Yujin, Villanueva, Augusto, Minguez, Beatriz, Tsai, Hung-Wen, Ward, Stephen C., Thung, Swan, Friedman, Scott L., Llovet, Josep M.
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2012
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3355195/
https://ncbi.nlm.nih.gov/pubmed/22322234
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jhep.2012.01.009
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge